Therapeutic efficacy of magnesium valproate in succinic semialdehyde dehydrogenase deficiency

JIMD Reports

Volumn 8, Issue , 2013, Pages 133-137

  Vanadia, Elena ^a   Gibson, K Michael ^b   Pearl, Phillip L ^c   Trapolino, Emanuele ^d   Mangano, Salvatore ^a   Vanadia, Francesca ^d  

^a UNIVERSITY OF PALERMO   (Italy)

^b WASHINGTON STATE UNIVERSITY   (United States)

^c GEORGE WASHINGTON UNIVERSITY SCHOOL OF MEDICINE AND HEALTH SCIENCES   (United States)

^d G Di Cristina Children Hospital   (Italy)

Author keywords

Complex partial seizure; Refractory status epilepticus; Ssadh deficiency; Status epilepticus; Urine organic acid analysis

Indexed keywords

EID: 84998589229     PISSN: 21928304     EISSN: 21928312     Source Type: Book Series    
DOI: 10.1007/8904_2012_170     Document Type: Chapter

References (22)

1. Akaboshi S, Hogema BM, Novelletto A, Malaspina P, Salomons GS, Maropoulos GD, Jakobs C, Grompe M, Gibson KM (2003) Mutational spectrum of the succinate semialdehyde dehydrogenase (ALDH5A1) gene and functional analysis of 27 novel disease-causing mutations in patients with SSADH deficiency. Hum Mutat 22(6):442–450
2. Buzzi A, Wu Y, Frantseva MV, Perez Velazquez JL, Cortez MA, Liu CC, Shen LQ, Gibson KM, Snead OC 3rd (2006) Succinic semialdehyde dehydrogenase deficiency: GABAB receptor-mediated function. Brain Res 1090(1):15–22
3. Chiron C, Dulac O (2011) Epilepsy: vigabatrin treatment and visual field loss. Nat Rev Neurol 7(4):189–190
4. Cortez MA, Wu Y, Gibson KM, Snead OC 3rd (2004) Absence seizures in succinic semialdehyde dehydrogenase deficient mice: a model of juvenile absence epilepsy. Pharmacol Biochem Behav 79(3):547–553
5. Dósa Z, Nieto-Gonzalez JL, Korshoej AR, Gibson KM, Jensen K (2010) Effect of gene dosage on single-cell hippocampal electrophysiology in a murine model of SSADH deficiency (gamma-hydroxybutyric aciduria). Epilepsy Res 90(1–2):39–46
6. Ergezinger K, Jeschke R, Frauendienst-Egger G, Korall H, Gibson KM, Schuster VH (2003) Monitoring of 4-hydroxybutyric acid levels in body fluids during vigabatrin treatment in succinic semialdehyde dehydrogenase deficiency. Ann Neurol 54(5):686–689
7. Gibson KM, Jakobs C, Ogier H, Hagenfeldt L, Eeg-Olofsson KE, Eeg-Olofsson O, Aksu F, Weber HP, Rossier E, Vollmer B et al (1995) Vigabatrin therapy in six patients with succinic semialdehyde dehydrogenase deficiency. J Inherit Metab Dis 18(2):143–146
8. Gropman A (2003) Vigabatrin and newer interventions in succinic semialdehyde dehydrogenase deficiency. Ann Neurol 54 (Suppl 6):S66–S72
9. Knerr I, Gibson KM, Jakobs C, Pearl PL (2008) Neuropsychiatric morbidity in adolescent and adult succinic semialdehyde dehydrogenase deficiency patients. CNS Spectr 13(7):598–605
10. Pandey M, Gupta A, Baduni N, Vijfdar H, Sinha S, Jain A (2010) Refractory status epilepticus–magnesium as rescue therapy. Anaesth Intensive Care 38(5):962
11. Pearl PL, Gibson KM, Acosta MT, Vezina LG, Theodore WH, Rogawski MA, Novotny EJ, Gropman A, Conry JA, Berry GT, Tuchman M (2003a) Clinical spectrum of succinic semialdehyde dehydrogenase deficiency. Neurology 60(9):1413–1417
12. Pearl PL, Novotny EJ, Acosta MT, Jakobs C, Gibson KM (2003b) Succinic semialdehyde dehydrogenase deficiency in children and adults. Ann Neurol 54(Suppl 6):S73–S80
13. Pearl PL, Gibson KM, Quezado Z, Dustin I, Taylor J, Trzcinski S, Schreiber J, Forester K, Reeves-Tyer P, Liew C, Shamim S, Herscovitch P, Carson RE, Butman JA, Jakobs C, Theodore WH (2009) Decreased GABA-A binding on FMZ-PET in succinic semialdehyde dehydrogenase (SSADH) deficiency. Neurology 73:423–429
14. Pearl PL, Shukla L, Theodore WH, Jakobs C, Michael Gibson K (2011) Epilepsy in succinic semialdehyde dehydrogenase deficiency, a disorder of GABA metabolism. Brain Dev 33(9):796–805
15. Porras-Kattz E, Harmony T, Ricardo-Garcell J, GalÄn L, FernÄndez T, Prado-AlcalÄ R, Avecilla-Ramírez G, SÄnchez-Moreno L, Barrera-Reséndiz J, Corsi-Cabrera M, Valencia-Solís E (2011) Magnesium valproate in learning disabled children with interictal paroxysmal EEG patterns: preliminary report. Neurosci Lett 492 (2):99–104
16. Saneto RP, Lee IC, Koenig MK, Bao X, Weng SW, Naviaux RK, Wong LJ (2010) POLG DNA testing as an emerging standard of care before instituting valproic acid therapy for pediatric seizure disorders. Seizure 19(3):140–146
17. Shinka T, Ohfu M, Hirose S, Kuhara T (2003) Effect of valproic acid on the urinary metabolic profile of a patient with succinic semialdehyde dehydrogenase deficiency. J Chromatogr B Analyt Technol Biomed Life Sci 792(1):99–106
18. Simler S, Ciesielski L, Klein M, Gobaille S, Mandel P (1981) Mechanism of action ofan anticonvulsant, sodium dipropylace-tate. C R Seances Soc Biol Fil 175(1):114–119
19. Visser NA, Braun KP, Leijten FS, van Nieuwenhuizen O, Wokke JH, van den Bergh WM (2011) Magnesium treatment for patients with refractory status epilepticus due to POLG1-mutations. J Neurol 258(2):218–222
20. Wong CG, Chan KF, Gibson KM, Snead OC (2004) Gamma-hydroxybutyric acid: neurobiology and toxicology of a recreational drug. Toxicol Rev 23(1):3–20
21. Wu Y, Buzzi A, Frantseva M, Velazquez JP, Cortez M, Liu C, Shen L, Gibson KM, Snead OC 3rd (2006) Status epilepticus in mice deficient for succinate semialdehyde dehydrogenase: GABAA receptor-mediated mechanisms. Ann Neurol 59(1):42–52
22. Zou LP, Wang X, Dong CH, Chen CH, Zhao W, Zhao RY (2010) Three-week combination treatment with ACTH + magnesium sulfate versus ACTH monotherapy for infantile spasms: a 24-week, randomized, open-label, follow-up study in China. Clin Ther 32(4):692–700